Janssen Inc. v. Teva Canada Ltd., 2020 FC 593
| Court | Federal Court (Canada) |
| Case Date | May 05, 2020 |
| Jurisdiction | Canada (Federal) |
| Citations | 2020 FC 593 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
38 practice notes
-
The Patented Medicines (Notice of Compliance) Regulations
...time limit). 116 PM(NOC) Regulations, above note 2, s 6(4). The Patented Medicines (Notice of Compliance) Regulations 231 Canada Ltd ., 2020 FC 593 at para 257; Regulations Amending the Patented Medicines (Notice of Compliance) Regulations, 2017 , SOR/2017-166, Regulatory Impact Assessment ......
-
Takeda Canada Inc. v. Apotex Inc., 2024 FC 106
...circumstances exist (Teva Canada Limited v Janssen Inc, 2023 FCA 68 at para 76-79; aff’g Janssen Inc v Teva Canada Ltd, 2020 FC 593 at para 272), I do not find this explanation compelling here. There is no evidence to suggest that a delayed release dosage form can function as a pul......
-
Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2020 FC 816
...of 2–20mg. The dosing of tadalafil, by involving a straightforward dosing regimen, is distinguishable from Janssen Inc v Teva Canada Ltd, 2020 FC 593, which involved a wholly different dosing regime: loading doses and maintenance doses. (3) Conclusion on anticipation [259] The Defendants ha......
-
Janssen Inc. v. Apotex Inc., 2022 FC 996
...product claims, and a product claim can be infringed by a product that is adapted for a patented use: Janssen Inc v Teva Canada Limited, 2020 FC 593 at paras 35, 252-256 [Teva Paliperidone]; Hospira Healthcare Corporation v Kennedy Trust for Rheumatology Research, 2018 FC 259 at paras 298-3......
Request a trial to view additional results
20 cases
-
Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2020 FC 816
...of 2–20mg. The dosing of tadalafil, by involving a straightforward dosing regimen, is distinguishable from Janssen Inc v Teva Canada Ltd, 2020 FC 593, which involved a wholly different dosing regime: loading doses and maintenance doses. (3) Conclusion on anticipation [259] The Defendants ha......
-
Janssen Inc. v. Apotex Inc., 2022 FC 996
...product claims, and a product claim can be infringed by a product that is adapted for a patented use: Janssen Inc v Teva Canada Limited, 2020 FC 593 at paras 35, 252-256 [Teva Paliperidone]; Hospira Healthcare Corporation v Kennedy Trust for Rheumatology Research, 2018 FC 259 at paras 298-3......
-
Janssen Inc. v. Pharmascience Inc., 2022 FC 62
...claims 1 to 48 of the 335 Patent against Teva Canada Limited [Teva] in Court File No. T-353-18 [Janssen Inc. v. Teva Canada Limited, 2020 FC 593 [Teva Paliperidone]]. [16] In Teva Paliperidone, I held, inter alia, that: An essential element of claim 1 is a continuous maintenance dose of 75 ......
-
Teva Canada Limited v. Janssen Inc., 2023 FCA 68
...N.V. (collectively, Janssen), cross-appeal from the judgment of the Federal Court (per Manson, J.) in Janssen Inc. v. Teva Canada Ltd., 2020 FC 593, 321 A.C.W.S. (3d) 539 , which was rendered in an action Janssen brought pursuant to subsection 6(1) of the Patented Medicines (Notice of Comp......
Request a trial to view additional results
16 firm's commentaries
-
Canadian Patent Law 2020: A Year In Review
...for incorporation by reference, the foreign prosecution history would have been admissible under section 53.1. Janssen v Teva, 2020 FC 593 [Janssen] involved an infringement pursuant to the Patented Medicines (Notice of Compliance) Regulations with respect to a Canadian patent. Evidence of ......
-
Whose Liability Is It Anyway? The Court Clarifies The Burden In Summary Trials And Infers Inducement
...1. ViiV Healthcare Company v. Gilead Sciences Canada, Inc., 2020 FC 486 [Viiv], aff'd 2021 FCA 122; Janssen Inc. v. Teva Canada Ltd., 2020 FC 593 [Teva], under appeal. 2. Teva at paras 35, 282, 290. 3. Pharmascience at para 88. Parts of the decision are redacted. Consequently, Pharmascience......
-
Whose Liability Is It Anyway? The Court Clarifies The Burden In Summary Trials And Infers Inducement
...1. ViiV Healthcare Company v. Gilead Sciences Canada, Inc., 2020 FC 486 [Viiv], aff'd 2021 FCA 122; Janssen Inc. v. Teva Canada Ltd., 2020 FC 593 [Teva], under appeal. 2. Teva at paras 35, 282, 290. 3. Pharmascience at para 88. Parts of the decision are redacted. Consequently, Pharmascience......
-
Dosing regimen patent found valid and infringed in the second decision under the new PM(NOC) Regulations
...need to use, or to induce the use, of the product. The case is: Janssen Inc. v Teva Canada Ltd, 2020 FC 593In the second trial judgment under the new Patented Medicine (Notice of Compliance) Regulations, the Federal Court (FC) found for the Plaintiffs, Janssen Inc. and Janssen Pharmaceutica......
Request a trial to view additional results
1 books & journal articles
-
The Patented Medicines (Notice of Compliance) Regulations
...time limit). 116 PM(NOC) Regulations, above note 2, s 6(4). The Patented Medicines (Notice of Compliance) Regulations 231 Canada Ltd ., 2020 FC 593 at para 257; Regulations Amending the Patented Medicines (Notice of Compliance) Regulations, 2017 , SOR/2017-166, Regulatory Impact Assessment ......